GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
== Recent research proposing reclassification == A March 2023 study published in Natural Products Research by Thanabalasingam et al. proposes that the double bond geometry in Coicenal A is of the (Z)- configuration rather than the originally proposed (E)- configuration. This claim was based on cross peak similarities between the nuclear Overhauser effect spectra of coicenal A and H-2 to H3-15 of oryazanigral, a heptaketide isolated from the endophytic fungus, Nigrospora oryzae. This study also proposes that Coicenals should not be classified as diterpenes since they contain a 6-oxabicyclo[3,2,1]oct-3-ene scaffold, characteristic of tricyclic heptaketides. Further research is needed to conclusively determine the proper classification of coicenals.
== Pathophysiology == As of 2026, the pathophysiology of fibromyalgia had not yet been elucidated. The prevailing view was that the fibromyalgia resulted from an amplification of pain by the central nervous system, but other hypotheses have also been suggested.
== Uses == MRS allows doctors and researchers to obtain biochemical information about the tissues of the human body in a non-invasive way (without the need for a biopsy), whereas MRI only gives them information about the structure of the body (the distribution of water and fat). For example, whereas MRI can be used to assist in the diagnosis of cancer, MRS could potentially be used to assist in information regarding to the aggressiveness of the tumor. Furthermore, because many pathologies appear similar in diagnostic imaging (such as radiation-induced necrosis and recurring tumor following radiotherapy), MRS may in the future be used to assist in distinguishing between similarly appearing prognoses. MRS equipment can be tuned (just like a radio receiver) to pick up signals from different chemical nuclei within the body. The most common nuclei to be studied are protons (hydrogen), phosphorus, carbon, sodium and fluorine. The types of biochemicals (metabolites) which can be studied include choline-containing compounds (which are used to make cell membranes), creatine (a chemical involved in energy metabolism), inositol and glucose (both sugars), N-acetylaspartate, and alanine and lactate which are elevated in some tumors. At present MRS is mainly used as a tool by scientists (e.g.
==== 1947–1965 ==== The United States under the Truman administration leaned towards favouring India in the late-1940s as a consequence of most U.S. planners seeing India more valuable diplomatically than neighboring Pakistan. However, during the Cold War, Nehru's policy of neutrality was cumbersome to many American observers. American officials perceived India's policy of non-alignment negatively. Ambassador Henry F. Grady told then-Indian Prime Minister Jawaharlal Nehru that the United States did not consider neutrality to be an acceptable position. Grady told the State Department in December 1947 that he had informed Nehru "that this is a question that cannot be straddled and that India should get on the democratic side immediately". In 1948, Nehru rejected American suggestions for resolving the Kashmir crisis via third party mediation. Nehru's 1949 tour of the United States was "an undiplomatic disaster" that left bad feelings on both sides. Nehru and his top aide V. K. Krishna Menon discussed whether India should "align with United States 'somewhat' and build up our economic and military strength." The Truman administration was quite favorable and indicated it would give Nehru anything he asked for. Nehru refused, and thereby forfeited the chance for a gift of one million tons of wheat.
Sources: en.wikipedia.org
== Chemical modification of amino acids == citrullination, or deimination, the conversion of arginine to citrulline deamidation, the conversion of glutamine to glutamic acid or asparagine to aspartic acid eliminylation, the conversion to an alkene by beta-elimination of phosphothreonine and phosphoserine, or dehydration of threonine and serine
Groth examined the change in symmetry of a crystal as a result of the replacement of a hydrogen atom by another univalent atom or radical. Morphotropy is also referred to as isogonism in which each vertex is surrounded by the same kinds of face in the same or reverse order, and with the same angles between corresponding faces. In 1897 Wilhelm Ostwald introduced Ostwald's rule, to describe the formation of polymorphs. The rule states that usually the less stable polymorph crystallizes first. Ostwald's rule is not a universal law but a common tendency observed in nature.
=== Significant dates === According to legend, the coffee plant was discovered in Ethiopia by a goat herder named Kaldi around 850 AD, who observed increased physical activity in his goats after they consumed coffee beans. First cultivation in India (Chikmagalur) – 1600 First cultivation in Europe – 1616 First cultivation in Java – 1699 First cultivation in Caribbean (Cuba, Hispaniola, Jamaica, Puerto Rico) – 1715–1730 First cultivation in Dutch East Indies – 1720 First cultivation in South America – 1730 Roasted beans first sold on retail market (Pittsburgh) – 1865 Various coffee extracts, and powdered instant coffee, developed in the late 19th century
The Philippines acquired 103 P-51D Mustangs after World War II, operated by the 6th "Cobras", 7th "Bulldogs" and 8th "Scorpions" tactical fighter squadrons of the 5th Fighter Wing. These became the backbone of the postwar Philippine Army Air Corps and Philippine Air Force, and were used extensively during the Huk campaign, fighting against communist insurgents, as well as the suppression of Moro rebels led by Hadji Kamlon in southern Philippines until 1955. The Mustangs were also the first aircraft of the Philippine air demonstration team, which was formed in 1953 and given the name the Blue Diamonds the following year. The Mustangs were replaced by 56 F-86 Sabres in the late 1950s, but some were still in service for COIN roles up to the early 1980s. Poland During World War II, five Polish Air Force in Great Britain squadrons used Mustangs. The first Polish unit equipped (7 June 1942) with Mustang Mk Is was "B" Flight of 309 "Ziemi Czerwieńskiej" Squadron (an Army Co-Operation Command unit), followed by "A" Flight in March 1943. Subsequently, 309 Squadron was redesignated a fighter/reconnaissance unit and became part of Fighter Command. On 13 March 1944, 316 "Warszawski" Squadron received their first Mustang Mk IIIs; rearming of the unit was completed by the end of April. By 26 March 1944, 306 "Toruński" Sqn and 315 "Dębliński" Sqn received Mustangs Mk IIIs (the whole operation took 12 days). On 20 October 1944, Mustang Mk Is in 309 Squadron were replaced by Mk IIIs.
Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens, but that are not structurally related to antibodies. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa. (Antibodies are ~150 kDa.) Nucleic acids and small molecules are sometimes considered antibody mimetics as well, but not artificial antibodies, antibody fragments and fusion proteins composed from these. Common advantages over antibodies are better solubility, tissue penetration, stability towards heat and enzymes, and comparatively low production costs. Antibody mimetics are being developed as therapeutic and diagnostic agents.
Sources: en.wikipedia.org
In the USA and other countries it was discontinued gradually after the introduction of the electroconvulsive therapy during the 1940s and the first neuroleptic drugs during the 1950s. Dr. Sakel died from heart failure on December 2, 1957, in New York City, NY, USA.
== Epidemiology == Sjögren's disease (SjD) is the third-most common rheumatic autoimmune disorder, behind rheumatoid arthritis and systemic lupus erythematosus. There are no geographical differences in the rates of Sjögren's. Sjögren's disease has been reported in all areas of the world, although regional rates have not been well studied. Depending on the criteria to determine prevalence, studies estimate the prevalence of Sjögren's at between 500,000 and 2 million people in the United States. Broader studies of Sjögren's prevalence vary widely, with some reports suggesting a prevalence of up to 3% of the population. A few studies have reported that the incidence of the syndrome ranges between three and six per 100,000 per year. Between 0.2 and 1.2% of the population is affected, with half having the primary form and half the secondary form. It is around 10 times more common in women than in men. Though the disease commonly begins in middle age, people of any age can be affected. Nine out of 10 Sjögren's patients are women. In addition to prevalence in women, having a first-degree relative with an autoimmune disease and previous pregnancies have been identified as epidemiological risk factors. Despite the lower risk for men, primary Sjögren's in men tends to represent a more severe form of the disease. The role of race and ethnicity in the prevalence of the disease is unknown. Although Sjögren's disease occurs in all age groups, the average age of onset is between 40 and 60. As many as half of all cases may be left undiagnosed or unreported.
== Structure == The chondrocyte in cartilage matrix has rounded or polygonal structure. The exception occurs at tissue boundaries, for example the articular surfaces of joints, in which chondrocytes may be flattened or discoid. Intra-cellular features are characteristic of a synthetically active cell. The cell density of full-thickness, human, adult, femoral condyle cartilage is maintained at 14.5 (±3.0) × 103 cells/ mm2 from age 20 to 30 years. Although chondrocyte senescence occurs with aging, mitotic figures are not seen in normal adult articular cartilage. The structure, density, and synthetic activity of an adult chondrocyte are various according to its position. Flattened cells are oriented parallel to the surface, along with the collagen fibers, in the superficial zone, the region of highest cell density. In the middle zone, chondrocytes are larger and more rounded and display a random distribution, in which the collagen fibers also are more randomly arranged. In the deeper zones, chondrocytes form columns that are oriented perpendicular to the cartilage surface, along with the collagen fibers. Different behaviors may be exhibited by chondrocytes depending on their position within the different layers. In primary chondrocyte cultures, these zonal differences in synthetic properties may persist. The primary cilia are significant for spatial orientation of cells in developing growth plate and are sensory organelles in chondrocytes. Primary cilia work as centers for wingless type (Wnt) and hedgehog signaling and contain mechanosensitive receptors.
===== ICONIC-ADVANCE 1 and 2 ===== The ICONIC-ADVANCE 1 and 2 studies are head-to-head phase III trials comparing icotrokinra to deucravacitinib (Sotyktu) in patients with moderate to severe plaque psoriasis. Both studies met their co-primary endpoints and demonstrated superiority of icotrokinra over deucravacitinib.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.